Items where authors include "Mease, PJ"

Article

McGonagle, D, McInnes, IB, Deodhar, A et al. (10 more authors) (2023) Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies. ACR Open Rheumatology, 5 (4). pp. 227-240. ISSN 2578-5745

Gladman, DD, Mease, PJ, Bird, P et al. (14 more authors) (2022) Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials, 23 (1). 743. ISSN 1745-6215

Orbai, A-M, Mease, PJ, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (4 more authors) (2022) Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies. BMC Rheumatology, 6 (1). 68. ISSN 2520-1026

Schreiber, S, Puig, L, Gonçalves, J et al. (3 more authors) (2022) Critical Appraisal and Future Outlook on Anti-Inflammatory Biosimilar Use in Chronic Immune-Mediated Inflammatory Diseases. Seminars in Arthritis and Rheumatism, 55. 152023. ISSN 0049-0172

Coates, LC, Soriano, ER, Corp, N et al. (42 more authors) (2022) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nature Reviews Rheumatology, 18 (8). pp. 465-479. ISSN 1759-4790

Mease, PJ, Helliwell, PS orcid.org/0000-0002-4155-9105, Gladman, DD et al. (14 more authors) (2021) Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. The Lancet Rheumatology, 3 (10). e715-e723. ISSN 2665-9913

Rahman, P, Mease, PJ, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (10 more authors) (2021) Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Research and Therapy, 23 (1). 190. ISSN 1478-6354

Coates, LC, Merola, JF, Mease, PJ et al. (10 more authors) (2020) Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. Rheumatology. keaa271. ISSN 1462-0324

Mease, PJ, Gladman, DD, Deodhar, A et al. (9 more authors) (2020) Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. RMD Open, 6 (2). e001217. ISSN 2056-5933

Goel, N, Coates, LC orcid.org/0000-0002-4756-663X, De Marco, G orcid.org/0000-0003-2406-161X et al. (11 more authors) (2020) GRAPPA 2019 Project Report. The Journal of Rheumatology Supplement, 96. pp. 53-57. ISSN 0380-0903

McInnes, IB, Mease, PJ, Kivitz, AJ et al. (9 more authors) (2020) Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. The Lancet Rheumatology, 2 (4). e227-e235. ISSN 2665-9913

Mease, PJ, Smolen, JS, Behrens, F et al. (11 more authors) (2020) A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Annals of the Rheumatic Diseases, 79 (1). pp. 123-131. ISSN 0003-4967

Coates, LC orcid.org/0000-0002-4756-663X, Wallman, JK, McGonagle, D et al. (9 more authors) (2019) Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies. Arthritis Research & Therapy, 21 (1). 266. ISSN 1478-6354

Chiarotto, A, Kaiser, U, Choy, E et al. (13 more authors) (2019) Pain measurement in rheumatic and musculoskeletal diseases: where to go from here? Report from a Special Interest Group at OMERACT 2018. Journal of Rheumatology, 46 (10). pp. 1355-1359. ISSN 0315-162X

Mease, PJ, Gladman, DD, Collier, DH et al. (5 more authors) (2019) Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. Arthritis & Rheumatology, 71 (7). pp. 1112-1124. ISSN 2326-5191

Goel, N, FitzGerald, O, Gladman, DD et al. (6 more authors) (2019) GRAPPA 2018 Project Report. The Journal of Rheumatology Supplement, 95. pp. 54-57. ISSN 0380-0903

Mease, PJ, Palmer, JB, Hur, P et al. (7 more authors) (2019) Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry. Journal of the European Academy of Dermatology and Venereology, 33 (5). pp. 886-892. ISSN 0926-9959

Cauli, A, Gladman, DD, Mathieu, A et al. (23 more authors) (2018) Physician’s Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. The Journal of Rheumatology, 45 (7). 171183. ISSN 0315-162X

Helliwell, PS, FitzGerald, O, Coates, LC et al. (2 more authors) (2017) GRAPPA 2016 Project Report. The Journal of Rheumatology, 44 (5). pp. 706-710. ISSN 0315-162X

Jadon, DR, Gladman, DD, Mease, PJ et al. (19 more authors) (2017) Proceedings of the GRAPPA 2016 Retreat. The Journal of Rheumatology, 44 (5). pp. 668-673. ISSN 0315-162X

Van der Heijde, D, Landewé, RB, Mease, PJ et al. (6 more authors) (2016) Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. Arthritis & Rheumatology, 68 (8). pp. 1914-1921. ISSN 2326-5191

Mease, PJ, Helliwell, PS, Boehncke, W-H et al. (5 more authors) (2016) GRAPPA 2015 Research and Education Project Reports. The Journal of Rheumatology, 43 (5). pp. 979-985. ISSN 0315-162X

Gladman, DD, Mease, PJ, Boehncke, W-H et al. (2 more authors) (2016) Presidential Round Table: A Report from the GRAPPA Annual Meeting. The Journal of Rheumatology, 43 (5). pp. 986-989. ISSN 0315-162X

Orbai, A-M, Mease, PJ, de Wit, M et al. (15 more authors) (2016) Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. The Journal of Rheumatology, 43 (5). pp. 965-969. ISSN 0315-162X

Taylor, AM, Taylor, JO, Singh, JA et al. (7 more authors) (2016) Ms. A.M. Taylor, et al reply. Journal of Rheumatology, 43 (4). pp. 826-827. ISSN 0315-162X

Ostergaard, M, Bird, P, Gandjbakhch, F et al. (14 more authors) (2015) The OMERACT MRI in Arthritis Working Group-Update on Status and Future Research Priorities. Journal of Rheumatology, 42 (12). pp. 2470-2472. ISSN 0315-162X

Keen, HI, Hensor, EMA, Wakefield, RJ et al. (3 more authors) (2015) Ultrasound assessment of response to intra-articular therapy in osteoarthritis of the knee. Rheumatology, 54 (8). 1385 - 1391. ISSN 1462-0324

Helliwell, PS, FitzGerald, O, Fransen, J et al. (34 more authors) (2013) The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Annals of the Rheumatic Diseases, 72 (6). pp. 986-991. ISSN 1468-2060

Conference or Workshop Item

Ritchlin, CT, Rahman, P, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (7 more authors) (2021) Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials. In: AAD VMX 2021, 23-25 Apr 2021, Virtual.

Mease, PJ, Coates, LC, Van den Bosch, F et al. (8 more authors) (2021) Correlation Between Skin Involvement, Joint Involvement and Enthesitis in Patients with Active Psoriatic Arthritis: Post-hoc Analysis of EQUATOR/EQUATOR2. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Kavanaugh, A, Liu, Y, Deodhar, A et al. (8 more authors) (2021) Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 Discover Program. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Helliwell, P orcid.org/0000-0002-4155-9105, Coates, LC, Van den Bosch, F et al. (7 more authors) (2021) The Effect of Filgotinib on Enthesitis: 100-Week Data from an Open-Label Extension Study in Patients with Active Psoriatic Arthritis. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Coates, LC, Mease, PJ, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Effect of Filgotinib on Pasdas: Drivers of Low and Very Low Activity up to Week 100. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Behrens, F, Mease, PJ, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Efficacy of Guselkumab Across Basdai Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Studies. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Orbai, AM, Mease, PJ, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (5 more authors) (2021) Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Coates, LC, Soriano, E, Corp, N et al. (31 more authors) (2021) The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment Recommendations 2021. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Coates, LC, Ritchlin, CT, Gossec, L et al. (12 more authors) (2021) Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Rahman, P, Helliwell, P orcid.org/0000-0002-4155-9105, Deodhar, A et al. (6 more authors) (2021) In Phase-3 Trials Discover 1 & 2, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue after Adjustment for Clinical Response (ACR20). In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Mease, PJ, Foley, P, Reich, K et al. (14 more authors) (2021) Low Incidence of Gastrointestinal-Related and Overall Serious Adverse Events among Guselkumab-Treated Patients: Pooled Analyses of Voyage 1 & 2 and Discover 1 & 2 Through 1-Year. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Ritchlin, CT, Rahman, P, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (13 more authors) (2021) Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis through 1 Year. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Behrens, F, Mease, PJ, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Efficacy of Guselkumab Across Basdai Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase-3, Randomized, Placebo-Controlled Studies. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Coates, LC, Ritchlin, CT, Gossec, L et al. (12 more authors) (2021) Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Coates, LC, Gladman, DD, Van den Bosch, F et al. (10 more authors) (2021) Long-Term Outcomes with Filgotinib, an Oral Preferential Janus Kinase 1 Inhibitor: 100-Week Data from an Open-Label Extension (OLE) Study in Patients with PSA. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Poddubnyy, D, Mease, PJ, Van den Bosch, F et al. (9 more authors) (2020) AB0824 WHICH PARAMETERS ARE RELEVANT IN THE IDENTIFYING AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS? – RESULTS OF A SURVEY AMONG ASAS AND GRAPPA MEMBERS. In: EULAR 2020, 03-06 Jun 2020, Online.

Gladman, DD, Coates, LC, Van den Bosch, F et al. (9 more authors) (2020) FRI0339 LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2). In: EULAR 2020, 03-06 Jun 2020, Online.

Helliwell, P, Van den Bosch, F, Coates, LC et al. (9 more authors) (2020) FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR). In: EULAR 2020, 03-06 Jun 2020, Online.

Husni, ME, Gladman, DD, Helliwell, P et al. (9 more authors) (2020) FRI0344 THE LONG-TERM EFFECT OF TREATING PSORIATIC ARTHRITIS WITH THE JANUS KINASE 1-SELECTIVE INHIBITOR FILGOTINIB ON LIPID PROFILES: AN ANALYSIS OF THE EQUATOR AND EQUATOR2 TRIALS. In: EULAR 2020, 03-06 Jun 2020, Online.

Rahman, P, Ritchlin, CT, Helliwell, P et al. (13 more authors) (2020) FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS. In: EULAR 2020, 03-06 Jun 2020, Online.

Helliwell, P, Gladman, DD, Poddubnyy, D et al. (13 more authors) (2020) OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES. In: EULAR 2020, 03-06 Jun 2020, Online.

Helliwell, P, Rahman, P, Deodhar, A et al. (6 more authors) (2020) SAT0421 GUSELKUMAB DEMONSTRATED AN INDEPENDENT TREATMENT EFFECT ON FATIGUE AFTER ADJUSTMENT FOR CLINICAL RESPONSE (ACR20) IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM PHASE-3 TRIALS DISCOVER 1 & 2. In: EULAR 2020, 03-06 Jun 2020, Online.

Proceedings Paper

Duarte-Garcia, A, Eder, L, Stephens-Shields, A et al. (13 more authors) (2018) Construct Validity of the Swollen and Tender Joint Counts for the Measurement of MSK Disease Activity in Psoriatic Arthritis. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .

Helliwell, P, Gottlieb, AB, Deodhar, AA et al. (8 more authors) (2018) The Effect of Guselkumab on Enthesitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .

Mease, PJ, Gladman, DD, van den Bosch, F et al. (10 more authors) (2018) Filgotinib, an Oral, Selective Janus Kinase 1 Inhibitor, Is Effective in Psoriatic Arthritis Patients with an Inadequate Response to Conventional Disease-Modifying Anti-Rheumatic Drugs: Results from a Randomized, Placebo-Controlled, Phase 2 Study. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .